Company Overview and News

 
Dimerix to lift cash following visit to World Congress for Clinical Trials in Diabetes

2017-12-01 proactiveinvestors.com.au
Dimerix Ltd (ASX:DXB) is a clinical stage biotechnology company, and has just finished presenting at the World Congress for Clinical Trials in Diabetes in Germany.
Upvote Downvote

 
Dimerix appoints Kathy Harrison inaugural full time CEO

2017-08-01 proactiveinvestors.com.au
Dimerix Ltd (ASX:DXB) has promoted Kathy Harrison to the inaugural full time chief executive officer of the company.
Upvote Downvote

 
Dimerix Ltd's valuation more than doubles after Kathy Harrison delivers results

2017-07-19 proactiveinvestors.com.au
Dimerix Ltd's (ASX:DXB) shares continue to rally on the back of positive results from its Phase 2a Trial of DMX-200 in Chronic Kidney Disease (CKD).
Upvote Downvote

 
Dimerix Ltd's shares rally on positive results from clinical trial

2017-07-12 proactiveinvestors.com.au
Dimerix Ltd (ASX:DXB) shares have rallied 18% in morning trade to $0.013, following the company revealing positive results from its Phase 2a Trial of DMX-200 in Chronic Kidney Disease (CKD).
Upvote Downvote

 
Dimerix Ltd to reveal Phase 2 trial results on Chronic Kidney Disease

2017-07-11 proactiveinvestors.com.au
Dimerix Ltd (ASX:DXB) is preparing to take investors through the results of its Phase 2 trial results on Chronic Kidney Disease, with the ASX granting the company a trading halt to prepare.
Upvote Downvote

 
Dimerix hosts key U.S. meetings ahead of final clinical data

2017-06-06 proactiveinvestors.com.au
Dimerix (ASX:DXB) has key news flow pending as it remains on-track to release final clinical data for its Phase 2 Dose Escalation study in chronic kidney disease in July.
Upvote Downvote

 
Dimerix: Access latest PPT from Proactive's CEO Sessions

2017-04-13 proactiveinvestors.com.au
Dimerix’ (ASX:DXB) chief executive officer, Kathy Harrison, joined Proactive's CEO Sessions in Melbourne on Tuesday, 11th April and Sydney on Wednesday, 12th April.
Upvote Downvote

 
Dimerix brings Phase II clinical trials to Proactive's Spotlight CEO Sessions

2017-04-03 proactiveinvestors.com.au
Dimerix (ASX:DXB) is a clinical stage biotechnology company, with a focus on Phase II clinical trials for chronic kidney disease.
Upvote Downvote

 
Proteomics International to outline pathway to market at Proactive's CEO Sessions

2017-03-27 proactiveinvestors.com.au
The company continues on a path to commercialisation as it advances deals with partners in Singapore and China to bring its PromarkerD, which is patented in both countries, to the Asian market.
Upvote Downvote

 
Southern Gold brings gold production to Proactive's Spotlight CEO Sessions

2017-03-27 proactiveinvestors.com.au
Southern Gold (ASX:SAU) is an under the radar company producing gold near Kalgoorlie through ore agreements with Westgold Resources (ASX:WGX).
Upvote Downvote

 
Dimerix receives cash injection from tax refund

2017-03-23 proactiveinvestors.com.au
Dimerix (ASX:DXB) has received $421,549 cash as part of the federal government research and development tax incentive program.
Upvote Downvote

 
Dimerix Bioscience Ltd surges in chronic kidney disease clinical trial

2016-06-06 proactiveinvestors.com.au
Dimerix Bioscience Ltd (ASX:DXB) is a biotechnology company advancing new drug therapies through the clinic for unmet medical needs.
Upvote Downvote

 

Related Articles

LPCN: Lipocine Inc Analysis and Research Report

11h - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...